Abstract
The diagnosis of recurrent or metastatic head and neck squamous cell cancer (HNSCC) confers an overall survival time of 6-9 months. Traditionally, frontline chemotherapy regimens consisted of platinumbased doublet regimen with either 5-fluorouracil or a taxane. However, in recent years, the addition of novel biologic agents has provided new options for the management of HNSCC. The following review will highlight the major studies that are reshaping the therapeutic landscape of HNSCC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 310-316 |
| Number of pages | 7 |
| Journal | Community Oncology |
| Volume | 6 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2009 |
ASJC Scopus subject areas
- Hematology
- Oncology